Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Oral CPSI-2364 in Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States, 66211
- Quintiles
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects meeting all of the following criteria will be considered for admission to the study:
- male or female between 18 and 55 years old inclusive;
- for females, the following conditions are to be met: all female subjects must be confirmed as not pregnant via serum pregnancy test; females must be of non-childbearing potential (defined as either surgically sterile or at least 1 year postmenopausal); or female subjects of childbearing potential must use 2 of the 3 following acceptable birth control methods from the time specified prior to the study through 60 days following the last dose of study drug: intrauterine contraceptive device (IUD) in place for at least 2 months prior to study; barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening; stable hormonal contraceptive for at least 3 months prior to study;
- in good health as determined by the Investigator based on medical history, physical examination, ECG, and clinical laboratory tests;
- with a body mass index (BMI) of 19 to 30 kg/m2, inclusive;
- nonsmokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the administration of the study medication), subjects must have nicotine levels below those measured for smokers (less than 400 ng/mL);
- agrees to abstain from alcohol intake 48 hours before each administration of study agent and during inpatient portion of the study (Days -1 to 2);
- agrees to limit caffeine/methylxanthine (e.g., coffee, tea, chocolate, or caffeine-containing soft drinks) intake to less than 300 mg/day for the duration of the study (300 mg of caffeine is equal to approximately 3 cups of coffee or 6 cola drinks);
- agrees not to consume food or beverages containing grapefruit juice, Seville oranges, or quinine (e.g., tonic water) from 72 hours prior to study Day -1 until after the last PK sample is collected;
- capable of understanding and complying with the protocol; willing and able to adhere to the study visit schedule and other protocol requirements;
- have no relevant food allergies (e.g., eggs or other components of standard clinic meals); and
- must have signed the informed consent document prior to performance of any study related procedures.
Exclusion Criteria:
- currently have, or have a history of, disease or dysfunction of the renal, hepatic, pulmonary, cardiovascular, endocrine, hematologic, neurological, immune, gastrointestinal, genitourinary, or other body system, that is clinically significant in the opinion of the Investigator;
- likely hypersensitivity or allergies to CPSI-2364, any components of CPSI-2364, or any drug within the same class of drug, minor drug allergies to a drug in other drug class may be approved by the Investigator if not considered of clinical relevance;
- any subject with a clinically significant mental or physical illness (in the opinion of the Investigator/Medical Advisor) within 1 year prior to the first dose, including a history of alcohol and/or drug abuse (as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th Edition guidelines) within 1 year prior to the first dose of study medication;
- abnormal pre-admission vital signs, 12-lead ECGs, and urinanalysis which are considered clinically significant by the Investigator and Sponsor (or designee);
- abnormal clinical laboratory evaluations, particularly abnormal creatinine, calculated GFR (abnormal defined as > 60 mL/min), and liver function tests. (Minor excursions from the normal range may be allowed if the clinical picture is otherwise normal and they are considered clinically insignificant by the Investigator and Sponsor [or designee]) ;
- any subject considering or scheduled to undergo any surgical procedure during the duration of the study;
- have an acute illness within 7 days prior to study agent administration or have had a hospitalization within 1 month prior to study agent administration;
- any subject who has received any known hepatic or renal clearance altering agents (eg, erythromycin, cimetidine, barbiturates, phenothiazines, or herbal/plant-derived preparations such as St. John's Wort, etc.) for a period of 90 days prior to the first dose of study medication;
- has a positive serology test for human immunodeficiency virus (HIV) antibodies, hepatitis A, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody at screening;
- has a positive urine drug screen for ethanol or substances of abuse including cocaine, cannabinoids, phencyclidine, amphetamines, benzodiazepines, barbiturates, opiates, propoxyphene, and methadone at screening and check-in(s);
- subject has donated plasma or blood within 30 days prior to the first dose of study medication or has a history of blood donation of more than 500 mL within 3 months prior to dosing;
- use of any prescription medications/products, except hormonal contraceptives, within 14 days prior to study entry, unless deemed acceptable by the Investigator;
- use of any over-the-counter (OTC) or nonprescription preparation (including minerals and phytotherapeutic/herbal/plant-derived preparations), within 14 days prior to dose administration, with the exception of ibuprofen and acetaminophen used at recommended doses. For acetaminophen a maximum of 1500 mg per day and no more than 3 g per week, will be allowed for the treatment of headache or other pain;
- any subject who does not meet the conditions for prior and concomitant treatments described in Section 8.8 Prior and Concomitant Therapy of this protocol;
- has taken any other investigational drug during the 30 days prior to Day -1;
- has any condition(s) that in the Investigator's opinion would: a) warrant exclusion from the study or b) prevent the subject from completing the study; or
- unable to understand verbal and/or written English or any other language in which a certified translation of the informed consent is available.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CPSI-2364 1 mg p.o.
Single dose
|
Single, oral dose of CPSI-2364 or placebo
Other Names:
|
|
Experimental: CPSI-2364 10 mg p.o.
single dose
|
Single, oral dose of CPSI-2364 or placebo
Other Names:
|
|
Experimental: CPSI-2364 30 mg p.o.
single dose
|
Single, oral dose of CPSI-2364 or placebo
Other Names:
|
|
Experimental: CPSI-2364 90 mg
single dose
|
Single, oral dose of CPSI-2364 or placebo
Other Names:
|
|
Experimental: CPSI-2364 270 mg p.o.
single dose
|
Single, oral dose of CPSI-2364 or placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety and tolerability of CPSI-2364
Time Frame: 7 days
|
7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetic profile of a single administration of oral CPSI-2364
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Phillip Leese, MD, Quintiles Phase I unit, Overland Park, KS
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Crohn Disease
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Semapimod
Other Study ID Numbers
Other Study ID Numbers
- 2364-CD-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.